Insilico acquires 38.6% stake in Daesung Microbiological via OTC purchase at KRW 11,000 per share, signaling premium valuation and enhanced shareholder value
Insilico acquired 1,466,740 common shares (38.6% stake) of Daesung Microbiological on March 24, 2026 via OTC purchase at KRW 11,000 per share.
The acquisition is part of a stock and management rights transfer agreement, making Insilico the de facto controlling shareholder.
The purchase price (KRW 11,000) represents a 65% premium over the current market price (KRW 6,650), indicating the acquirer's high valuation of Daesung's intrinsic value.
Potential strategic changes may follow the change in control, with the new majority shareholder's business direction and performance improvement being key variables for future stock price.
[AI Comprehensive Analysis]This disclosure signifies a major change in controlling shareholder, and the premium acquisition sends a positive signal about the company's value. While it may fuel short-term price momentum, long-term shareholder value hinges on the new management's ability to execute strategy.
KOSDAQ Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders